An Open-Label Study to Evaluate the Pharmacokinetics of a Single Oral Dose of 300 mg JNJ-28431754 (Canagliflozin) in Subjects With Various Degrees of Impaired Hepatic Function Compared With Subjects With Normal Hepatic Function.

Trial Profile

An Open-Label Study to Evaluate the Pharmacokinetics of a Single Oral Dose of 300 mg JNJ-28431754 (Canagliflozin) in Subjects With Various Degrees of Impaired Hepatic Function Compared With Subjects With Normal Hepatic Function.

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Feb 2015

At a glance

  • Drugs Canagliflozin (Primary)
  • Indications Liver disorders
  • Focus Pharmacokinetics
  • Most Recent Events

    • 14 Jul 2011 Actual end date (April 2011) added as reported by ClinicalTrials.gov.
    • 14 Jul 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Oct 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top